Focus: Spyre Therapeutics is a publicly traded antibody-focused biotechnology company headquartered in Waltham, MA, specializing in immunology therapeutics. The company is in early-stage clinical development with no approved products generating minimal revenue.
Profile data last refreshed 11h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
3 added, 2 removed. Backfill posture.
High-risk, high-upside early-stage play suitable only for scientists/operators comfortable with startup volatility and willing to bet on antibody biology in immunology.
Help build intelligence for Spyre Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Spyre Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Spyre Therapeutics Announces Grants of Inducement Awards The Manila Times
New Spyre Therapeutics hires get $70.54 stock option grants - Stock Titan
New Spyre Therapeutics hires get $70.54 stock option grants Stock Titan
Spyre Therapeutics (SYRE) CEO Turtle sells 15,000 shares in pre-set 10b5-1 trades - Stock Titan
Spyre Therapeutics (SYRE) CEO Turtle sells 15,000 shares in pre-set 10b5-1 trades Stock Titan
Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options - Stock Titan
Spyre Therapeutics (SYRE) CMO sells 8,333 shares, retains 313,334 options Stock Titan
Spyre CFO sells 7,500 shares after option exercise | SYRE Insider Trading - Stock Titan
Spyre CFO sells 7,500 shares after option exercise | SYRE Insider Trading Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing - Stock Titan
[144] Spyre Therapeutics, Inc. SEC Filing Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo